Citizens Maintains Market Outperform on Taysha Gene Therapies, Raises Price Target to $11
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Citizens analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and raises the price target from $8 to $11.
Citizens analyst Silvan Tuerkcan maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Market Outperform and raises the price target from $8 to $11.